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Abstract: The expression and clinical significance of insulin-like growth factor 1 (IGF-1), 
insulin-like growth factor binding protein 3 (IGFBP-3), and insulin-like growth factor bind-
ing protein 7 (IGFBP-7) were investigated in serum and lung cancer tissues from 57 patients 
with non-small cell lung cancer (NSCLC). Lung cancer tissues at different pathologic stages 
(27 patients at stages I–II and 30 patients at stages III–IV), normal lung tissues from 17 patients 
with benign pulmonary disease, and serum samples from both lung cancer and benign pulmonary 
disease patients were collected during surgery. Enzyme-linked immunosorbent assay and avidin-
biotin-peroxidase complex immunohistochemical staining were used to detect IGF-1, IGFBP-3, 
and IGFBP-7 expression in serum and tissues, respectively. The results show that expression 
of IGF-1 in lung cancer tissues and serum from NSCLC patients were significantly higher than 
in the control (P , 0.05). However, expression of IGFBP-3 and IGFBP-7 in cancer tissues 
and serum from NSCLC patients was significantly lower than in the control (P , 0.05). These 
results suggest that upregulation of IGF-1 and downregulation of IGFBP-3 and IGFBP-7 may 
be potential diagnostic biomarkers for NSCLC.
Keywords: insulin-like growth factor 1, insulin-like growth factor binding protein 3, insulin-like 
growth factor binding protein 7, non-small cell lung cancer, diagnostic biomarkers
Introduction
Lung cancer is the second most common cancer in men and women and a leading 
cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) 
representing approximately 85% of all cases.1 In addition, more than one half of 
affected patients have advanced metastasis with a poor prognosis. According to the 
International Agency for Research on Cancer of World Health Organization, lung 
cancer is the most common cancer in the world, with an estimated 1.6 million new 
cases in 2008, representing one in eight of all new cancers. It is also the most common 
form of cancer death in the world, comprising nearly one in five of all deaths from 
cancer.1 In the People’s Republic of China, lung cancer has been the predominant type 
of cancer in males.2
Tumorigenesis can be induced by out-of-control cell proliferation and apoptosis 
or cell cycle dysfunction. In recent years, studies have demonstrated that, by binding 
to receptors, the insulin-like growth factor family (IGFs) can initiate the cell signal 
transduction pathway, promote cell mitosis, proliferation, and differentiation, and 
inhibit cell apoptosis. This, in turn, may play an important role in tumor occurrence OncoTargets and Therapy 2013:6 submit your manuscript | www.dovepress.com
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and development.3 The biological effect of IGFs after binding 
to their receptors is regulated by a series of specific insulin-
like growth factor binding proteins (IGFBPs).4 Research 
evidence shows that IGFs have mitogenic and antiapoptotic 
properties; they have been implicated in the development 
of lung cancer, and the effects of IGFs are modulated by 
IGFBPs.5,6 The rationale for measuring the fasting level of 
these proteins in peripheral blood is that, due to the anabolic 
nature of these proteins, fasting allows for normalization. 
To elucidate the relationship between IGF-1/IGFBPs and 
NSCLC, the expression of IGF-1, IGFBP-3, and IGFBP-7 in 
serum and lung tissues from NSCLC patients and controls 
were analyzed in this study.
Materials and methods
Materials
Enzyme-linked immunosorbent assay (ELISA) kits for IGF-1 
and IGFBP-3, a hematoxylin and eosin staining kit, Mayer’s 
hematoxylin, and avidin-biotin complex stain were purchased 
from Wuhan Boster Biological Technology, Ltd (Wuhan, 
People’s Republic of China). An IGFBP-7 ELISA kit was 
purchased from Shanghai Jintai Biological Technology, Ltd. 
(Shanghai, People’s Republic of China). The ELISA reader 
was a MultiskanMK3, purchased from Shanghai Zhili Sci-
entific Instrument Company Ltd., China (Shanghai, People’s 
Republic of China). Rabbit anti-human IGF-1, IGFBP-3, and 
IGFBP-7 polyclonal antibodies were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). ELISA kits were 
purchased from Beijing Zhongshan Golden Bridge Biotech-
nology Co., Ltd. (Beijing, People’s Republic of China).
Methods
Selection of NSCLC and control cases
Fifty-seven surgical inpatients with NSCLC (March through 
November 2010) from the department of thoracic surgery 
at the Affiliated Hospital of Guangdong Medical College 
(Zhanjiang, Guangdong, People’s Republic of China) 
were selected as NSCLC cases, including 38 males and 
19 females aged 27–84 years. According to the Union for 
International Cancer Control 2009 tumor, node, metastasis 
(TNM) staging standard for lung cancers and the World 
Health Organization histologic type classification standard 
for lung cancer, 19 cases were identified as squamous cell 
carcinoma and 38 cases as adenocarcinoma, with 27 patients 
being at stage I–II and 30 patients being at stage III–IV. 
During the same time period, seven male and ten female 
surgical inpatients aged 33–75 years with benign pulmonary 
disease were selected as the control group. These included 
three cases of bronchiectasis, five cases of inflammatory 
pseudotumor, five cases of   tuberculosis ball, three cases of 
bronchial cyst, and one case of pulmonary sequestration. 
All NSCLC and control cases were diagnosed by pathologic 
examination (double-blind assessment by three patholo-
gists) in the pathology department of the Affiliated Hospital 
of Guangdong Medical College. No case had preoperative 
chemotherapy or radiotherapy. Patients with diabetes or 
other metabolic disorders were excluded. In addition, human 
specimens collected for this study after surgical operations 
had been approved by the ethics committee of the Affiliated 
Hospital of Guangdong Medical College. All patients had 
provided their written consent to participate in this study.
serum collection and elisa
Before treatment, fasting peripheral venous blood (5 mL) 
was collected from all participants in the morning. Blood 
samples were kept at room temperature for 30 minutes, and 
then centrifuged at 150 g for 20 minutes. Supernatant serum 
was collected and stored at -20°C until use. Serum IGF-1, 
IGFBP-3, and IGFBP-7 levels were then analyzed using 
ELISA according to the manufacturer’s instructions.
Lung tissue collection, avidin-biotin complex 
immunohistochemistry, and hematoxylin  
and eosin staining
The tumorigenic tissues were harvested from the NSCLC 
patients during surgery. Normal lung tissues were harvested 
from the outer region of the lesions from control patients dur-
ing surgery. All tissues were immediately fixed in 4% formalin 
for histopathologic examination. The formalin-fixed tissues 
were stored at 4°C until examination. Tissues were processed 
using standard histology laboratory techniques. Using a 
microtome, 3–4 µm sections were cut. These were then stained 
with avidin-biotin complex immunohistochemical stain fol-
lowing a standard staining protocol to detect expression of 
IGF-1, IGFBP-3, and IGFBP-7. Briefly, sections were treated 
with 3% peroxide in methanol for 15 minutes to block endog-
enous peroxidase activity, followed by overnight incubation 
with the primary antibody at 4°C. Mouse primary monoclonal 
antibodies directed against IGF-I, IGFBP-3, and IGFBP-7 
(1:100 dilution; Santa Cruz Biotechnology) were used in 
these experiments. After rinsing with phosphate-buffered 
saline, secondary biotinylated antisera were followed by the 
avidin-biotin complex (Wuhan Boster Biological Technology); 
the reaction was developed with 3-39-diaminobenzine-tetra-
hydrochloride and counterstained with Mayer’s hematoxylin. 
IGF-I, IGFBP-3, and IGFBP-7 immunoreactivity was graded OncoTargets and Therapy 2013:6 submit your manuscript | www.dovepress.com
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according to the relative immunostaining intensity (IGF-I, 
IGFBP-3, and IGFBP-7 stain intensity). Hematoxylin and 
eosin staining was conducted according to the manufacturer’s 
instructions for indicating the pathology.
statistical analysis
Statistical analyses were performed using Statistical Pack-
age for the Social Sciences version 17 software (SPSS Inc., 
Chicago, IL, USA). Two-samples mean comparison was 
analyzed by t-test. Multiple-sample mean comparison was 
analyzed by one-way analysis of variance. According to 
homogeneity variance results, the least squares difference 
test was used for data analyses when variance was equal, 
but Tamhane’s T2 test was used when variance was unequal. 
The mutual relationship between two growth factors was 
analyzed by Pearson correlation analysis. The intragroup 
and intergroup expression difference detected by immuno-
histochemistry assay was analyzed by the rank-sum test. The 
correlation of two ranked data was analyzed by   Spearman 
correlation analysis. The mean method was used to compare 
the means of measurement data among different groups. Eta 
and Eta square values were used to measure the correlation. 
Statistical significance was set at P , 0.05.
Results
Comparison of serum IGF-1, IGFBP-3, 
and IGFBP-7 expression between  
nsclc and controls
The t-test showed that the concentration of IGF-1 in the serum 
from NSCLC cases (159.24 ± 44.74 µg/L) was significantly 
higher than that from control cases (128.79 ± 25.40 µg/L, 
P = 0.034). However, the concentration of IGFBP-3 in the 
serum from NSCLC cases (1299.58 ± 328.87 µg/L) was signifi-
cantly lower than that of control cases (1611.56 ± 405.08 µg/L, 
P = 0.042). The concentration of IGFBP-7 in serum from 
NSCLC cases (32.51 ± 14.05 ng/L) was also significantly 
lower than that from control cases (43.81 ± 18.32 ng/L, 
P = 0.026, Figure 1).
Stratification analysis of pathologic 
parameters and serum IGF-1, IGFBP-3, 
and IGFBP-7 concentrations in NSCLC 
cases
Stratification analysis showed that concentrations of IGF-1, 
IGFBP-3, and IGFBP-7 in the serum of NSCLC cases had 
no significant (P . 0.05) association with the location of 
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Figure 1 Comparison of serum IGF-1, IGFBP-3, and IGFBP-7 expression between NSCLC and control cases.
Abbreviations: IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein 3; IGFBP-7, insulin-like growth factor binding protein 7; NSCLC, 
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NSCLC, diameter of the tumor, or pathologic grade or type, 
but was significantly (P , 0.05) associated with levels of 
lymph node metastasis, local invasion, distant metastasis, 
and TNM stage (Table 1).
Correlation analysis of serum IGF-1  
and IGFBP-3 or IGFBP-7 concentrations 
in nsclc cases
Pearson correlation analysis showed that the concentrations 
of IGF-1 and IGFBP-3 in the serum of NSCLC cases had 
a significant negative correlation (r = -0.253, P = 0.023), 
but there was no correlation between the concentrations of 
IGF-1 and IGFBP-7 in serum from NSCLC cases (r = -0.151, 
P = 0.272).
IGF-1, IGFBP-3, and IGFBP-7 expression 
in nsclc tissue and normal control  
lung tissue
The intensity of IGF-1, IGFBP-3, or IGFBP-7 expression in 
lung tissues from NSCLC cases was detected by avidin-biotin 
complex immunohistochemical staining (Figure 2).   Pathology 
was shown by hematoxylin and eosin staining (Figure 3). 
IGF-1 expression in lung cancer tissues from NSCLC cases 
progressed from weakly positive to strongly positive, which 
was significantly stronger than that (mainly from negative 
to weak positive) in normal lung tissues from control cases 
Table 1 Stratification analysis on pathologic parameters and serum concentrations of IGF-1, IGFBP-3, and IGFBP-7 of NSCLC cases 
(mean ± standard deviation)
Pathologic  
parameters
Classification Case 
number
IGF-1 
(μg/L)
P IGFBP-3 
(μg/L)
P IGFBP-7 
(ng/L)
P
location central type 17 157.36 ± 26.70 0.454 1314.21 ± 388.22 0.751 39.94 ± 16.43 0.307
peripheral type 40 164.92 ± 37.41 1283.37 ± 309.89 28.86 ± 18.45
Tumor  
diameter
d # 3 cm 18 157.36 ± 36.57 0.363 1347.88 ± 373.77 0.675 29.93 ± 10.08 0.367
3 cm , d # 7 cm 34 167.89 ± 32.98 1267.65 ± 308.93 37.72 ± 25.81
d . 7 cm 5 148.40 ± 36.59 1246.79 ± 357.19 42.37 ± 20.67
Pathologic  
grade
High differentiation 11 158.60 ± 30.16 0.739 1431.36 ± 382.31 0.143 32.63 ± 12.66 0.537
Middle differentiation 19 160.06 ± 36.10 1316.87 ± 268.95 35.29 ± 22.11
Low differentiation 27 166.71 ± 36.04 1206.49 ± 338.97 41.86 ± 31.91
lymph node 
metastasis
no 25 148.69 ± 26.61 0.023 1488.95 ± 340.81 0.001 39.98 ± 20.09 0.043
Yes 32 170.23 ± 36.21 1240.47 ± 319.50 30.16 ± 14.36
local invasion T1–T2 39 153.29 ± 32.32 0.001 1372.42 ± 335.27 0.004 42.45 ± 16.02 0.032
T3–T4 18 184.76 ± 29.73 1104.67 ± 240.96 31.25 ± 13.70
Distant  
metastasis
no 43 151.74 ± 28.19 0.002 1375.63 ± 16.81 0.001 49.25 ± 34.06 0.006
Yes 14 193.27 ± 32.78 1060.08 ± 260.84 31.05 ± 19.19
Pathologic  
type
squamous carcinoma 18 154.72 ± 28.27 0.222 1288.63 ± 349.29 0.950 37.53 ± 24.81 0.664
adenocarcinoma 39 166.65 ± 36.56 1294.54 ± 327.63 34.81 ± 20.41
TnM stage i–ii 26 151.21 ± 29.95 0.016 1412.69 ± 327.87 0.008 39.31 ± 20.80 0.034
iii–iV 31 172.98 ± 35.54 1184.45 ± 301.30 28.34 ± 16.37
Abbreviations: TNM, tumor, node, metastasis; NSCLC, non-small cell lung cancer; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein 3; 
IGFBP-7, insulin-like growth factor binding protein 7.
(40.57 versus 27.21, P , 0.05). IGFBP-3 expression in lung 
cancer tissues from NSCLC cases progressed from negative 
to positive, and was significantly weaker than its expression in 
control cases (from positive to strong positive) (34.62 versus 
47.15, P , 0.05). IGFBP-7 expression in lung cancer tissues 
from NSCLC cases progressed from negative to positive, 
also significantly weaker than its expression in control cases 
(30.77 versus 40.40, P , 0.05, rank-sum test).
IGF-1, IGFBP-3, and IGFBP-7 expression 
in lung cancer tissues and stratification 
analysis with pathologic parameters  
of NSCLC cases
Stratification analysis showed that the intensity of IGF-1, 
IGFBP-3 and IGFBP-7 expression had no significant associa-
tion (P . 0.05) with location of the lung tissue, tumor diam-
eter, histologic type, or pathologic grade, but had a significant 
(P , 0.05) association with stage III–IV TNM, lymph node 
metastasis, and distance metastasis parameters (Table 2).
Correlation analysis of intensity of IGF-1 
with IGFBP-3 or IGFBP-7 expression in 
lung tissues from NSCLC cases
Spearman’s rank correlation analysis showed that there was 
no significant correlation between the expression intensity of 
IGF-1 and IGFBP-3 (rs = 0.224, n = 57, P = 0.062).   However, OncoTargets and Therapy 2013:6 submit your manuscript | www.dovepress.com
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levels of IGFBP-7 expression intensity in lung tissues from 
NSCLC cases.
Discussion
IGF-1, a growth hormone, was first identified by Salmon and 
Daughaday in 1957, and since then the function of growth 
hormone-IGF in regulating cell growth and apoptosis has 
been widely investigated.3 IGF-1 is produced primarily by 
the liver as an endocrine hormone as well as in target tis-
sues in a paracrine/autocrine fashion.7 Its primary action is 
mediated by binding to its receptor, the insulin-like growth 
factor 1 receptor (IGF-1R), present on many cell types in 
many   tissues. IGF-1R then stimulates systemic body growth, 
and has growth-promoting effects on almost every cell in 
Figure 2 Intensity of IGF-1, IGFBP-3, or IGFBP-7 expression in lung tissues at 
different stages of squamous carcinoma of the lung. (A) IGF-1 expression in stage Ia 
squamous carcinoma of the lung, slightly positive (yellow-brown staining). (B) IGF-1 
expression in stage IIb squamous carcinoma of the lung, strongly positive. (C) IGFBP-3 
expression in stage Ia lung squamous carcinoma, strong positive. (D) Expression of 
IGFBP-3 in IIb stage squamous carcinoma of the lung, slightly positive. (E) IGFBP-7 
expression in stage Ia squamous carcinoma of the lung, strongly positive. (F) IGFBP-7 
expression in stage IIb squamous carcinoma of the lung, slightly positive. All figures 
were captured under the microscope at 200× magnification.  lung tumor tissue 
areas; → normal lung tissue areas.
Abbreviations: IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth 
factor binding protein 3; IGFBP-7, insulin-like growth factor binding protein 7.
Figure 3 Pathology of normal lung tissue and stage Ia and IIb of squamous carcinoma 
of the lung. (A) Normal lung tissue, (B) stage Ia squamous carcinoma of the lung, and 
(C) stage IIb squamous carcinoma lung tissue. All figures were captured under the 
microscope at 200× magnification.
there was a significant negative correlation between the 
expression intensities of IGF-1 and IGFBP-7 (rs = -0.437, 
n = 57, P = 0.001).
Association of IGF-1, IGFBP-3,  
or IGFBP-7 concentrations in serum  
and expression intensity in lung  
tissues from NSCLC cases
Serum IGF-1 concentrations were significantly different 
(P , 0.05), with a positive correlation (Eta = 0.369) at differ-
ent levels of IGF-1expression intensity in lung cancer tissues 
from NSCLC cases shown by the measures of association 
test. Serum IGFBP-3 concentrations showed no significant 
differences (P . 0.05), with a slight positive correlation 
(Eta = 0.079) at different levels of IGFBP-3 expression 
intensity in lung tissues from NSCLC cases. Serum IGFBP-7 
concentrations showed no significant differences (P . 0.05), 
with a slight positive correlation (Eta = 0.144) at different OncoTargets and Therapy 2013:6 submit your manuscript | www.dovepress.com
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Table 2 Stratification analysis on association of expression of IGF-1, IGFBP-3, and IGFBP-7 in lung tissues and its pathologic parameters 
in nsclc cases
Pathologic 
parameters
Classification Case 
number
IGF-1 
average rank
P IGFBP-3 
average rank
P IGFBP-7 
average rank
P
location central type 17 27.95 0.435 26.95 0.121 32.94 0.112
Peripheral type 40 31.47 33.82 27.33
Tumor diameter #3 cm 18 24.39 0.253 33.26 0.131 25.97 0.181
3 cm , d # 7 cm 34 30.80 25.55 28.93
d . 7 cm 5 34.60 35.60 40.40
Pathologic grade High differentiation 11 20.25 0.071 27.58 0.857 24.09 0.707
Middle differentiation 19 29.53 28.30 29.63
Low differentiation 27 32.78 30.24 30.56
lymph node  
metastasis
no 25 23.10 0.036 37.85 0.001 32.16 0.011
Yes 32 32.19 24.22 26.53
local invasion T1–T2 39 25.94 0.025 37.24 0.009 32.83 0.039
T3–T4 18 34.30 25.50 28.62
Distant metastasis no 43 26.36 0.032 32.60 0.003 30.77 0.014
Yes 14 36.40 18.93 23.57
Pathologic type squamous carcinoma 18 28.82 0.950 32.68 0.199 32.42 0.219
adenocarcinoma 39 29.09 27.16 27.42
TnM stage i–ii 26 24.07 0.024 33.96 0.020 31.92 0.038
iii–iV 31 33.43 24.53 26.55
Abbreviations: TNM, tumor, node, metastasis; NSCLC, non-small cell lung cancer; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein 3; 
IGFBP-7, insulin-like growth factor binding protein 7.
the human body. In addition to its insulin-like effects, IGF-
1R can also regulate cell growth and   development. IGF-1R 
seems to have assumed an important role, especially in can-
cer biology.8 In recent years, studies have shown that IGF-1 
can enhance expression and activity of the latent form of 
urokinase-type plasminogen activator, matrix metallopro-
teinase-2, matrix metalloproteinase-9, and promotes cancer 
cell invasion.9,10 The IGFBPs are a family of homologous 
proteins that have coevolved with the IGFs.11 Normally, the 
amount of IGFBP-3 in the serum is very low, but it can be 
increased under certain physiologic or pathologic conditions 
like pregnancy, surgery, or malignancy.12 A study by Oh et al 
showed that IGFBP-3 can effectively prevent urokinase-type 
plasminogen activator and matrix metalloproteinase-9 from 
stimulating the invasion pathways, and ultimately reduce 
metastasis of lung cancer cells.13 Chen et al14 investigated 
138 patients with lung cancer and 20 cases of normal 
lung tissue by immunohistochemistry and confirmed that 
insulin-like growth factor binding protein-related protein 1 
(IGFBP-rP1) had high expression levels in normal tissues 
and low expression levels in cancer tissues. Moreover, by 
polymerase chain reaction sequencing and in nude mice 
experiments, they found that IGFBP-rP1 could inhibit tumor 
growth rate, increase the number of apoptotic cells, and acti-
vate expression of caspase-3.14 IGFBP-rPl plays a role as a 
tumor suppressor in human lung cancer by downregulating 
the methylation of DNA.14
The spread of cancer involves multiple steps, including 
cell adhesion to extracellular matrix-specific glycoprotein, 
prevention of the degraded extracellular matrix composition 
migrating out of the blood vessels via tumor-related protein, 
and local invasion.15,16 Our results show that IGF-1 expres-
sion in NSCLC cases was significantly higher than that in 
the benign lung lesion cases, and expression was increased 
as malignant lung cancer progression occurred, suggesting 
that IGF-1 has a greater capacity for promoting mitosis 
in lung cancer.17 The high level of IGF-1 expression may 
play an important role in the development of lung cancer, 
promoting proliferation of cancer cells and inhibiting their 
apoptosis. In this study, we also found that, in cases with 
lymph node metastasis, distant metastasis, invasion of the 
chest wall, pericardium, or great vessels, or at TNM stages 
III–IV , the concentrations or expression of IGF-1 in serum or 
lung cancer tissues was significantly higher than in patients 
without lymph node metastasis, distant metastasis, local 
invasion, invasion of the visceral pleura, or at TNM stage 
I–II. This result suggests that IGF-1 may be involved in local 
invasion and distant metastasis of lung cancers. Therefore, 
the serum IGF-1 concentration and intensity of its expression 
in lung cancer tissues may have clinical significance in early 
diagnosis and prediction of NSCLC. A new molecular target 
therapy that regulates the level of IGF-1 expression or blocks 
IGF-1 from binding with its cell surface receptor might be 
useful in the treatment of NSCLC.OncoTargets and Therapy 2013:6 submit your manuscript | www.dovepress.com
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In addition, we found that the concentration of 
IGFBP-3 in serum in NSCLC cases was significantly 
lower than in controls, and there were a negative correla-
tion between the concentrations of IGF-1 and IGFBP-3 in 
serum. Under circumstances of lymph node metastasis, 
distant metastasis, invasion of the chest wall, pericardium, 
or great vessels, or TNM stage III–IV, the concentration 
or expression of IGFBP-3 in serum and lung cancer tissue 
was significantly lower than that in patients without lymph 
node metastasis, distant metastasis, local invasion or only 
invasion of the visceral pleura, or TNM stage I–II. These 
results suggest that regulation of IGFBP-3 by IGF-1 may 
be through binding with IGF-1 and then inhibiting its 
effect of promoting differentiation and proliferation of 
tumor cells. In an in vitro experiment, Alami et al18 found 
that recombinant human IGFBP-3 could inhibit prolif-
eration of M-3LL lung cancer cells in a dose-dependent 
manner, and could also significantly inhibit tumor growth 
after M-3LL cell transplantation in mice. Although no cor-
relation between concentrations of IGF-1 and IGFBP-7 in 
the serum from NSCLC cases was found in this study, 
the expression of IGFBP-7 decreased as the lung cancer 
progressed, suggesting that IGFBP-7 may also be a lung 
cancer inhibitor.
In conclusion, our results suggest that expression of IGF-
1, IGFBP-3, and IGFBP-7 in serum and lung tissues may 
play an important role in the development of lung cancer. 
Detection of IGF-1, IGFBP-3, and IGFBP-7 in the peripheral 
serum could be significant in risk assessment of lung can-
cer patients, early prediction of the presence or absence of 
potential lymph node metastasis and distant metastasis, and 
thereby guide clinical treatment. Upregulation of IGF-1 and 
downregulation of IGFBP-3 and IGFBP-7 may be potential 
diagnostic biomarkers for NSCLC. To reduce the circulating 
and local expression of IGF-1 and enhance IGFBP-3 and 
IGFBP-7 levels in the body may become one of the targets 
of lung cancer treatment in future.
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